Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole

被引:30
|
作者
Abed, Mohammed N. [1 ,2 ]
Alassaf, Fawaz A. [1 ,3 ]
Jasim, Mahmood H. M. [1 ,2 ]
Alfahad, Mohanad [1 ,4 ]
Qazzaz, Mohannad E. [1 ,5 ]
机构
[1] Univ Mosul, Coll Pharm, Mosul, Iraq
[2] Univ Mosul, Dept Pharmaceut Chem, Mosul, Iraq
[3] Univ Mosul, Dept Pharmacol & Toxicol, Mosul, Iraq
[4] Univ Mosul, Dept Pharmaceut, Mosul, Iraq
[5] Univ Mosul, Dept Pharmacognosy & Med Plants, Mosul, Iraq
关键词
Peptic ulcer; Proton pump inhibitors; Oxidative damage; Free radicals; alpha; alpha-Diphenyl-beta-picrylhydrazyl; Antioxidants; HELICOBACTER-PYLORI INFECTION; IN-VITRO ANTIOXIDANT; OXIDATIVE STRESS;
D O I
10.1159/000506232
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Peptic lesions usually develop when there is an imbalance between aggressive drivers and gastro-protective mediators that guard the lining of the gastrointestinal tract. The most crucial of these mediators are antioxidants, whose loss may predispose to oxidative stress, which is believed to be the main aggravator of several diseases including peptic ulcer. Proton pump inhibitors (PPIs) are drugs that are highly effective and widely used for therapeutic management of peptic disorders through inhibition of gastric acid secretion. In spite of this, oxidative damage may continue to be a major issue that can predispose to future lesions. Objective: The present study is designed to explore the possible antioxidant capability of different PPIs, including omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole, in an aim to suggest an agent that, in addition to its acid-suppression properties, can provide antioxidant profit. Methods: The antioxidant activity of different PPIs was evaluated calorimetrically to test the ability of each drug to quench oxygen free radical, using the well-known stable free radical alpha,alpha-diphenyl-beta-picrylhydrazyl (DPPH), and compared to ascorbic acid (AA; vitamin C). The measurements were performed using a spectrophotometer at 517 nm. Results: All the studied drugs reduced DPPH, but to different extents. However, omeprazole and esomeprazole showed the highest ability to scavenge free radicals (50% inhibitory concentrations [IC(50)s] of the percentage for free radical scavenging activity are 18.7 +/- 5.7 and 18.7 +/- 5.7, respectively, and the AA equivalents are 83,772 +/- 11,887 and 81,732 +/- 8,523 mg AA/100 g, respectively). Conversely, lansoprazole, pantoprazole, and rabeprazole might be having no role in this story (IC(50)s of the percentage for free radical scavenging activity are 49.3 +/- 3.1, 49 +/- 9.4, and 40.7 +/- 7.2, respectively, and the AA equivalents are 30,458 +/- 3,884, 32,222 +/- 10,377, and 37,876 +/- 8,816 mg AA/100 g, respectively). Conclusion: Thus, omeprazole and esomeprazole may confer a significant dual action in gastrointestinal protection by providing potent antioxidant properties in addition to their major role as acid-suppression agents. However, further studies are essential to elucidate the mechanism behind the difference between the drugs of the same class. (C) 2020 S. Karger AG, Basel
引用
收藏
页码:645 / 651
页数:7
相关论文
共 50 条
  • [1] Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
    Li, XQ
    Andersson, TB
    Ahlström, M
    Weidolf, L
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) : 821 - 827
  • [2] Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
    Thomson A.B.
    [J]. Current Gastroenterology Reports, 2000, 2 (6) : 482 - 493
  • [3] Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs
    Meyer, UA
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 : S21 - S25
  • [4] Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study
    Miner, P
    Katz, PO
    Chen, YS
    Sostek, M
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12): : 2616 - 2620
  • [5] The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism
    Insogna, Karl L.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S2 - S4
  • [6] Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication:: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole
    Levine, A
    Shevah, O
    Shabat-Sehayek, V
    Aeed, H
    Boaz, M
    Moss, SF
    Niv, Y
    Avni, Y
    Shirin, H
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (01) : 117 - 122
  • [7] Proton pump-inhibiting drugs, calcium homeostasis, and bone health
    Wright, Matthew J.
    Proctor, Deborah D.
    Insogna, Karl L.
    Kerstetter, Jane E.
    [J]. NUTRITION REVIEWS, 2008, 66 (02) : 103 - 108
  • [8] Pharmacokinetics and effect an caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
    Andersson, T
    Holmberg, J
    Röhss, K
    Walan, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (04) : 369 - 375
  • [9] Diarrhea Caused by Proton Pump Inhibitor Administration: Comparisons Among Lansoprazole, Rabeprazole, and Omeprazole
    Shimura, Shino
    Hamamoto, Naoharu
    Yoshino, Nagisa
    Kushiyama, Yoshinori
    Fujishiro, Hirofumi
    Komazawa, Yoshinori
    Furuta, Kenji
    Ishihara, Shunji
    Adachi, Kyoichi
    Kinoshita, Yoshikazu
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2012, 73 (03): : 112 - 120
  • [10] Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection -: comparison with omeprazole and lansoprazole
    Miwa, H
    Ohkura, R
    Murai, T
    Sato, K
    Nagahara, A
    Hirai, S
    Watanabe, S
    Sato, N
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) : 741 - 746